"Intervacc completed commercial scale production of the antigens (drug substance) for several million doses of Strangvac. On 25 November Intervacc announced that, together with partners 3P Biopharmaceuticals and LIOF-Pharma (prev. Praxis Pharmaceuticals), it completed the manufacturing process for Strangvac with the previously produced antigens. 60,000 vaccine doses have been manufactured and released, which are also expected to be sold if Strangvac receives market approval."
Länk till uppdragsanalys nedan.